Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00003348 · ClinicalTrials.gov registry record · Phase 1

Carmustine Plus O(6)-Benzylguanine in Treating Patients With Recurrent or Progressive Gliomas of the Brain

A Phase 1 study of Brain and Central Nervous System Tumors, sponsored by Duke University.

Completed
Registry status
Phase 1
Development phase
56
Enrollment target
1
Study location

NCT00003348: Completed Phase 1 study of Brain and Central Nervous System Tumors, sponsored by Duke University.

NCT00003348 is a Phase 1 study of Brain and Central Nervous System Tumors that has completed, run by Duke University. The registered enrollment target is 56 participants, below the 182-participant average among 45 other Brain and Central Nervous System Tumors trials with a reported enrollment target (69% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00003348, a Phase 1 study of Brain and Central Nervous System Tumors, has completed, sponsored by Duke University.

COMPLETED
Registry status
Phase 1
Development phase
56 participants
Enrollment target
1
Study location

Study Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of carmustine plus O(6)-benzylguanine in treating patients who have recurrent or progressive gliomas of the brain.

Conditions Studied

Brain and Central Nervous System Tumors

Interventions

  • DRUG O6-benzylguanine
  • DRUG carmustine

Study Locations (1)

North Carolina

  • Duke Comprehensive Cancer Center - Durham

Trial Details

FieldValue
Enrollment Target 56 participants
Start Date 1998-05
Est. Completion 2000-08
Phase Phase 1
Duke University

1,725 total trials

What the finished NCT00003348 record still lists

NCT00003348 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 56 participants, a relatively small participant target, below the 182-participant average among 45 other Brain and Central Nervous System Tumors trials with a reported enrollment target (69% lower).

The record links to 1 condition, with Brain and Central Nervous System Tumors appearing as the primary indexed condition, and to 2 interventions - of which O6-benzylguanine is the first listed.

NCT00003348 reports a single indexed study location in North Carolina.

Frequently Asked Questions

What is clinical trial NCT00003348 about?

NCT00003348 is a clinical study titled "Carmustine Plus O(6)-Benzylguanine in Treating Patients With Recurrent or Progressive Gliomas of the Brain". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of carmustine plus O(6)-benzylguanine in treating patients who have recur...

What is the current status of trial NCT00003348?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 56 participants. The study started on 1998-05. Estimated completion is 2000-08.

What conditions does trial NCT00003348 study?

This clinical trial studies the following conditions: Brain and Central Nervous System Tumors.

What interventions are being tested in trial NCT00003348?

The interventions under investigation include: O6-benzylguanine (DRUG), carmustine (DRUG).

Who is sponsoring clinical trial NCT00003348?

This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00003348 being conducted?

This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Brain and Central Nervous System Tumors

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00003348's enrollment target sits among peer trials

56 21st of 45 higher than 24 of 45 other Brain and Central Nervous System Tumors trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Brain and Central Nervous System Tumors trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02287428 · 56 participants · Phase 1

    Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBM

  • NCT02923011 · 56 participants · Phase 3

    Comparative Effectiveness of MRgFUS Versus CTgRFA for Osteoid Osteomas

  • NCT02935283 · 56 participants

    Neuroimaging and Neuropsychological Outcomes in Urea Cycle Disorders

  • NCT03375866 · 56 participants · NA

    Effects of Mixed Nut Consumption on Satiety and Weight Management

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Related registry views

Source: ClinicalTrials.gov NCT00003348, the US trial registry maintained by the National Library of Medicine. NCT00003348 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.